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http://dx.doi.org/10.1016/j.jaip.2016.10.010METHODS: An online survey of symptom experience, impact
on daily life, and management was conducted in US respondents
who suffer (or whose child suffers) from SARC symptoms.
RESULTS: A total of 1001 surveys were completed: 500 adults
(‡18 years old) and 501 children (12-17 years old, documented by
their parents). Similar to earlier AR surveys, SARC symptoms
negatively affected the patient’s (and family’s) quality of life, and
were most severe in the spring. Before being treated, >50% of
respondents reported daily symptoms during their season; 75% to
80% considered their symptoms moderate to severe. Patients saw a
variety of health care professionals (including pharmacists) and
used over-the-counter and prescription medications for symptoms.
Those using prescription medications were generally more satisﬁed
with treatment and less likely to switch or discontinue treatment.
Nasal and/or ocular symptoms drove adherence, seeing a health
care professional, and reviewing and/or changing treatment.
CONCLUSIONS: The majority of patients with SARC report
moderate-to-severe symptoms that signiﬁcantly impair their
quality of life. However, patients appear to be taking more re-
sponsibility for their (child’s) condition, and patient expecta-
tions for therapy are increasingly being met. Continued efforts
will be needed to examine the contribution of better information
and/or increased access to and availability of medications to
control the disease.  2016 The Authors. Published by Elsevier
Inc. on behalf of the American Academy of Allergy, Asthma &
Immunology. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/). (J Allergy Clin Immunol Pract 2016;-:---)
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Seasonal nasal and ocular allergy, often referred to as seasonal
allergic rhinoconjunctivitis (SARC) and sometimes as “hay1
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2 MELTZER ETALTABLE I. Key outcomes of phone and paper surveys of patients
with allergic rhinitis and health care professionals (HCPs) whoAbbreviations used
treat those patients in the United States4,5,9,13-17AR- Allergic rhinitisHCP- Health care professional
In previous surveys patients with allergic rhinitis and HCPs reported that:INAH- Intranasal antihistamine
The worst season for nasal and eye allergy symptoms was spring.INCS- Intranasal corticosteroid
The most bothersome symptom was nasal congestion/stufﬁness/blockedOTC- Over the counternose.QoL- Quality of life
Nasal and ocular allergy symptoms negatively affected physical andSARC- Seasonal allergic rhinoconjunctivitisemotional health, daily activities, cognitive ability, and productivity,
and contributed to missed work and school days.
Patients used over-the-counter and prescription medications to reduce
their symptoms—predominantly oral nonsedating antihistamines and
intranasal corticosteroids.
Treatment dissatisfaction was high, and reﬂected incomplete relief, slow
onset of relief, duration of relief less than 24 h, and/or a sense of
reduced efﬁcacy with use over time.
Inadequate efﬁcacy was the primary reason for discontinuing or
changing medications.
Nasal and ocular allergy exacerbated comorbid conditions, particularly
asthma and rhinosinusitis.fever,” is a common chronic disease, estimated to affect upward
of 16% of the population of the United States in any one year.1-3
Although estimates of the incidence and prevalence can vary
widely depending on the speciﬁc population and analyses
used,3,4 trends indicate that neither has diminished despite a
better understanding of the condition, new pharmacological and
immunological treatments, and increased access to care. Indeed,
patient-reported and/or physician-diagnosed seasonal nasal and
ocular symptoms seem to have become more common.3,5-8
Patients commonly report bothersome symptoms affecting
the nose (congestion, sneezing, itching, rhinorrhea) and eyes
(itching, redness, watering, swelling) that can vary in fre-
quency, intensity, and seasonality. The underlying mucosal
inﬂammation also can exacerbate other conditions, and
symptoms can impair patients’ quality of life (QoL).4,6 For
children in particular, symptoms can negatively impact family
and daily activities.9 Management requires a multifaceted
approach for most individuals, and the patient (and/or parent/
caregiver) needs to understand the disease, its variability, and
how and when treatment works to optimize clinical out-
comes.3,7,8,10 Standard approaches to manage SARC include
environmental control methods, pharmacotherapy, and
immunotherapy; patient education is critical for day-to-day
care.3,10 Discussion of management is beyond the scope of
this paper, and readers are directed to several excellent reviews
as well as current guidelines.3,7,8,10-12 The goal of treatment is
control of the disease, which translates to minimal symptoms
and improved well-being and ability to function for the patient
(and family).3,6-8,10
Data reported over the past 15 years from surveys of in-
dividuals with nasal allergies in the United States and health care
professionals (HCPs) who treat these individuals illustrate how
burdensome allergic rhinitis (AR) can be (Table I).4,5,9,13-17 The
surveys included patients with both perennial and seasonal al-
lergy symptoms, and many patients had a combination of year-
round symptoms that became worse in certain seasons. No
survey focused predominantly on patients with seasonal allergy.
Overall, the ﬁndings suggested that the impact of AR and its
management had been underestimated, and conversations have
ensued regarding best approaches for improving outcomes.
Whether the outcomes have changed since then is of interest,
particularly with the availability of newer drug products (eg,
aerosolized intranasal corticosteroids [INCS], intranasal antihis-
tamines [INAH], INAHþINCS combination, sublingual
immunotherapy), increased over-the-counter (OTC) access to
medications, and continued discussion of best paths to man-
agement. This paper describes an online survey undertaken to
assess patients’ perceptions of SARC, its impact on daily life, and
its management.METHODS
Survey
The survey was conducted online in the United States between
March 2 and March 9, 2015, by Nielsen Consumer Insights on
behalf of the Asthma and Allergy Foundation of America. The in-
clusion criteria for survey respondents were as follows:
 Ages 18 years or older
 Personally suffers (or has a child, aged 12-17 years, who suffers)
from nasal and/or ocular symptoms of seasonal allergies
 Conﬁrmed by a physician based on the question “Have you been
told by a doctor that you have (or your child has) any of the
following conditions.” as shown in Appendix E1, available in
this article’s Online Repository at www.jaci-inpractice.org
 Has sought treatment from a medical professional for SARC
symptoms for themselves or their child in the past year
The survey was designed to be approximately 15 minutes in
length and to obtain information on patient and/or parent per-
spectives of the burden of nasal and ocular seasonal allergy symptoms
occurring at a time when they (their child) typically experienced
symptoms (as opposed speciﬁcally to the week of survey adminis-
tration). Survey design was similar to earlier phone surveys4,5,9,13-17
but updated given the availability of newer prescription and OTC
medications since those surveys were conducted. The survey is
shown in Appendix E1, available in this article’s Online Repository
at www.jaci-inpractice.org.
Sample source
The sample source was derived from a Harris Poll panel of re-
spondents for online consumer research supplemented by similar
online panels from various Nielsen research partners. The sample was
pulled randomly to provide a national census representation of re-
spondents who met the inclusion criteria. To efﬁciently screen for
parents of children with SARC, individuals preidentiﬁed from known
panel statistics as parents of children (<18 years) were targeted.
Email invitations were sent to a total of 79,839 potential re-
spondents with a password protected link, so that each link could
only be used once.
TABLE II. Patient demographics and characteristics at the time of
survey
Characteristic
Adults
(n [ 500)
Children
(n [ 501)
Gender, %
Male 45 54
Female 55 46
Mean age, y (range) 50.5 (18-88) 14.6 (12-17)
Ethnicity, % *
Caucasian 76 66
Hispanic 10 21
Black/African American 11 9
Asian/Paciﬁc Islander 1 2
Region of the United States, % *
East 23 22
Midwest 19 21
West 18 18
South 40 35
Diagnosed and allergy tested by a
physician, %
74 84
Mean age at ﬁrst diagnosis,† y (range) 24.4 (1-75) 8.5 (1-18)
Under care of health professional at the
time of survey, %z
Primary care physician 58 35
Pediatrician 1 30
Nurse practitioner 6 7
Allergy specialist 14 24
Ear, nose, and throat doctor 10 10
Pharmacist 5 5
Otherx 2 e
None 21 12
Education *
High school or less 26 27
Some or completed college 50 47
Some or completed graduate school 14 14
*Ethnicity and education level were recorded for the responding parent.
†Mean age of patients diagnosed by a physician.
zMore than one response allowed; total may exceed 100%.
xIncluded asthma specialist, dermatologist, homeopath, internist, neurologist,
ophthalmologist, physician assistant, pulmonologist as speciﬁed by respondents.
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The total data were weighted to represent the general population
of 18 year olds and parents of children (12-17 years old), and then
were combined proportionally into a representative total. Weighting
was based on the demographics of the adult respondent, and the
weighting variables included age by gender, household income, ed-
ucation, race and/or ethnicity, region, and whether or not a parent.
Propensity score weighting was used to adjust for respondents’
propensity to be online.
Because the sample is based on respondents who agreed to
participate in market research surveys, estimates of theoretical sam-
pling error could not be calculated.
RESULTS
A total of 1001 surveys were collected: 500 adults (18 years
old) and 501 children (12-17 years old as documented by their
parents). Table II presents the patients’ characteristics at the time
of the survey. All patients suffered from SARC and had sought
medical treatment for their symptoms. Approximately 74% of
the adults and 84% of children had been tested for their seasonal
allergies. Throughout this paper, the term “patients” refers to
adult respondents (and/or to their children) who suffer from
nasal and/or ocular symptoms of seasonal allergies.
Patients’ condition
Themajority of patients experienced nasal and/or ocular allergy
symptoms in the spring (adults 95%, children 92%), thoughmore
than 60% of patients also reported symptoms in the summer and
the fall (Figure 1). Approximately 20% of adults and 21% of
children reported experiencing symptoms year round. The sea-
sonal triggers listed by patients are shown in Table III.
Patients reported spring allergy symptoms as theworst, bothwhen
asked about the season with the worst symptoms (spring, 64%;
summer, 16%; fall, 15%; winter, 6%) and when asked to classify the
severity of their (or their child’s) symptoms by season (Figure 2).
Almost all patients experienced symptoms at least monthly
(adults, 93%; children, 91%) during their reported allergy
season(s). Approximately half had daily symptoms (adults,
57%; children, 46%). The single most bothersome symptoms
for which patients sought treatment are shown in Figure 3.
Before treatment, most patients rated their overall symptoms
as moderate (adults, 43%; children, 50%) or severe (adults,
45%; children, 38%); the symptoms rated as most severe were
nasal congestion (adults, 46%; children, 42%) and stuffy nose
(adults, 33%; children, 36%). The severity ratings and the
symptom terminology were evaluated according to the re-
spondents’ interpretation of their symptom experience. No
guidance was provided as to what mild, moderate, or severe
might entail, nor for the different terms for nasal congestion.
Impact of seasonal allergy symptoms
SARC had substantial negative impact, physically, mentally,
and emotionally (Figure 4). When asked about productivity,
performance, concentration, and feelings, more than 50% of
patients (adults and children) reported impairment of daily ac-
tivities and/or increased levels of distraction, irritability, fatigue,
and frustration when suffering from symptoms of SARC. Pa-
tients also reported feeling unhappy, upset, and angry, and
expressed negative self-images in relation to their symptoms.
Approximately 9 of 10 patients experienced at least some
disruption of sleep due to their allergy symptoms; forapproximately 40%, symptoms affected sleep “a lot” (Table IV).
Symptom-related interference with daily leisure and/or social
activities and productivity at work or school was considerable,
with approximately one-third experiencing “a lot” of interfer-
ence. When subsequently asked to estimate days of lower pro-
ductivity per month with allergy symptoms, 82% of adults and
91% of children reported being less productive at work and/or
school for at least 1 day/month. Approximately 50% of patients
(adults, 48%; children, 54%) experienced 6-20 days of dimin-
ished productivity. The mean estimates for days of lost pro-
ductivity related to seasonal allergy symptoms were 9.3 for adults
and 10.2 for children in a typical seasonal allergy month.
Management
Most patients saw an HCP due to their nasal and/or ocular
allergy symptoms more than once a year, and children generally
saw their HCPs more frequently than adults (Table E1, available
in this article’s Online Repository at www.jaci-inpractice.org).
TABLE III. Reported triggers of seasonal allergy nasal/ocular
symptoms (% patients)
Trigger Adults (n [ 500) Children (n [ 501) Total (N [ 1001)
Tree pollen 75% 75% 75%
Grass pollen 69% 77% 71%
Weed pollen 69% 70% 69%
Mold spores 52% 52% 52%
Other* 16% 4% 13%
Don’t know 8% 7% 8%
*As speciﬁed by respondents, this included dust/dust mites, ﬂower pollen, animal
dander, blooming plants, insects, chemicals, humidity, perfumes, and/or unknown.37%
74%
63%
95%
% PaƟents
Spring Summer Fall Winter
FIGURE 1. Season(s) when patients experienced nasal and/or eye
allergy symptoms. Base ¼ all qualified respondents, N ¼ 1001.
Respondents were asked to indicate all that applied.
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pharmacist for care. In most cases, the patient (or parent) initi-
ated the discussion about different treatment options for their
(child’s) allergy symptoms (adults, 69%; children, 61%). Of
these, 5% or fewer initiated the discussion because of adver-
tisements (TV, print, internet) or recommendations (family,
friends) for speciﬁc medications. Patients used a wide range of
products to manage their (child’s) symptoms (Figure 5). The
speciﬁc classes of allergy medications being used by respondents
or their children at the time of the survey are shown in Table V.
Antihistamines (oral, intranasal) were the most commonly used
medication, both OTC and prescription.
When asked about how they chose what to use to treat SARC
symptoms, most respondents reported either only taking medi-
cations recommended by their physician or pharmacist (adults,
39%; children, 47%) or taking recommended medications but
sometimes supplementing with other OTC medications for
speciﬁc symptoms (adults, 27%; children, 30%). The remainder
used OTC medications without the beneﬁt of a health pro-
fessional’s recommendation.
Symptoms and symptom onset were the primary signals to
take allergy medication for 47% of adults and 46% of children.
However, some respondents reported using allergy medication
daily and year round (adults, 41%; children, 28%) either because
of symptoms or “to ward off symptoms.” Only 12% of adults
and 26% of children started their allergy medications before
seasonal symptom onset.
Symptoms and symptom onset were also the key signals for re-
evaluating care. Respondents most commonly reassessed care
“when symptoms are no longer managed with current care”
(adults, 57%; children, 47%, difference statistically signiﬁcant at
95% conﬁdence level) and “at the beginning of each allergy
season” (adults, 22%; children, 43%, difference statistically sig-
niﬁcant at the 95% conﬁdence level).
Respondents reported switching between brands, formulations,
and type of medication (OTC, prescription) over time (Figure 6).
Patients taking OTC medications were more likely to change
brands and formulations compared with patients using onlyprescription medications (35% and 20%, respectively). Approxi-
mately 15% of respondents reported adding OTC medications to
supplement what their (child’s) doctor prescribed. Switching be-
tween OTC and prescription medications also was cited—
approximately 18% of patients switched from prescription medi-
cations to only using OTC medications; approximately 11% of
patients switched from OTC medications to only using
prescriptions.
Satisfaction with treatment
Patients were asked about their satisfaction with the effec-
tiveness of various types of treatments for SARC symptoms.
Satisfaction was rated highest for allergy injection immuno-
therapy (shots) (adults, 94%; children, 95%), though only 10%
of patients were treated this way (Figure 5). Prescription medi-
cations had the next highest satisfaction ratings, and nonpre-
scription OTC medications the lowest. Nonetheless, the
satisfaction ratings for all classes of medications were fairly high.
For adults, the ratings were: allergy shots (94%) > prescription
oral allergy medications (83%) > prescription seasonal nasal
sprays, overall (78%) > OTC oral allergy medications (69%) >
OTC seasonal sprays, overall (64%). For children, the ratings
were slightly higher with less between-class differentiation: al-
lergy shots (95%) > prescription oral allergy medication (87%)
z prescription seasonal nasal sprays (88%) > OTC seasonal
sprays (81%) z OTC oral allergy medication (79%). The
various nasal sprays were not speciﬁed as to type.
Effectiveness, providing consistent relief from SARC symp-
toms, and few side effects were the three most important criteria
in patient ratings of their allergy treatments (Figure 7). Quick
relief, ease of use, and cost considerations while ranked lower
were important considerations for most patients. Under a sepa-
rate query, most patients agreed that their current medications
met the criteria previously rated as important (Figure 8).
Cost and compliance considerations
When asked about changes in the cost of medications for their
SARC symptoms over the past year, about half of the patients
reported that costs have remained the same, regardless of whether
they were using OTC or prescription medications. The
remainder was more likely to report their medications having
increased in price—36% of patients using prescription medica-
tions and 40% of those using OTC medications.
Cost was an important criterion for treatment (Figure 7).
Seventy-two percent of patients who preferred an OTC medi-
cation noted that it was important that the medication be within
their budget. For those using prescription medications, 69% and
65%, respectively, cited “covered by my prescription plan” and
0% 5% 10% 15% 20% 25%
None of these
Itching
Itchy eyes
Stuﬀy nose
Sneezing
Runny nose
Headaches/Sinus pain
CongesƟon
Adults (n=500)
Children (n=501)
FIGURE 3. The single most bothersome symptom for which treatment was sought for the respondent or the respondent’s child. Base ¼
all qualified respondents, N ¼ 1001.
18%
24%
21%
35%
47%
54%
65%
53%
35%
23%
15%
12%
Spring (n=465)
Summer (n=274)
Fall (n=334)
Winter (n=145)
17%
20%
18%
32%
44%
58%
59%
54%
38%
22%
23%
14%
Spring (n=468)
Summer (n=304)
Fall (n=375)
Winter (n=180)
Mild Moderate Severe
Adults Children 
FIGURE 2. Respondents’ classification of their/their child’s seasonal allergy (nasal/eye) symptoms, by season. Base ¼ all qualified re-
spondents, N ¼ 1001. Respondents were asked to indicate all that applied.
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to a subsequent query, most patients agreed that their current
SARC medications met these criteria: available OTC and within
budget, 67%; covered by prescription plan, 89%; available at
lowest copay, 83% (Figure 8).
About two-thirds of patients reported taking their medication
exactly as prescribed or recommended. Another 20% reported
only using their medication(s) when they (their child) had
symptoms. The remainder indicated effort at keeping to di-
rections, but sometimes not following them. Patients who
perceived their symptoms as “severe” were more likely to take
their medications exactly as prescribed/recommended (severe,
50%; moderate, 32%; mild, 31%). The reasons given for not
taking medications as prescribed are shown in Figure 9.
Those who did not take their medications as prescribed were
asked: “What would make it easier for you/your child to takeyour/his/her allergy medications exactly as prescribed?” Fewer
side effects (42%), lower cost (36%), and more convenient
dosing schedule (33%) were key (Figure 10).DISCUSSION
This is the ﬁrst reported online survey for AR. Despite dif-
ferences in survey methodologies and subject characteristics, the
outcomes of the current survey support the ﬁndings of earlier
questionnaires regarding patient perceptions of the expression,
impact, and management of AR nasal and ocular symptoms (see
Table I).4,5,9,13-17 Before treatment, more than 50% of the
SARC respondents experienced symptoms daily during an allergy
month; 75% to 80% considered symptoms to be moderate or
severe. Symptoms were reported as most severe in the spring, and
in more than 50% of adults and children, seasonal nasal and/or
0% 10% 20% 30% 40% 50% 60% 70%
None of these
Indiﬀerent/Don't care
Embarrassed
Less confident
UnaƩracƟve
Angry
Upset
Distracted
Having poor concentraƟon
Unhappy
UnproducƟve/Having reduced producƟvity
Unable to perform at my/his or her best
Frustrated
Tired
Irritable
Adults (n=500)
Children (n=501)
*
*
*
*
*
*StaƟsƟcally significant at 95% confidence level
FIGURE 4. Physical and emotional impact of seasonal allergy (nasal/eye) symptoms. Base ¼ all qualified respondents, N ¼ 1001. Re-
spondents were asked to select all that applied.
TABLE IV. Respondent ratings of how much their/their child’s
seasonal allergy symptoms (nasal/ocular) interfered with daily
activities
Interfered Productivity at work or school Leisure/social activities Sleep
A lot 28% 33% 38%
A little 49% 52% 49%
Not at all 24% 15% 13%
Note. The data apply to both adults and children (base ¼ total respondents, N ¼
1001).
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QoL. More than 90% reported disrupted sleep (40%, “a lot”).
Exacerbation of comorbid conditions (eg, asthma, rhinosinusitis)
by seasonal allergy symptoms was reported in the earlier surveys,
but was not included in the current questionnaire. However, the
consequence of worsening any of the many comorbidities further
underscores the overall morbidity of AR.
This survey updates and expands information on treatment
satisfaction from the patient’s perspective. All treatments for
SARC had relatively high satisfaction ratings, with immuno-
therapy the highest at 95% of respondents. Unfortunately, this
was provided to only 10% of patients. Prescription medications,
both oral and intranasal, had higher ratings than OTC medica-
tions. The satisfaction ratings for prescription oral and intranasal
medications were very close: 83% and 77%, respectively, for
adults, and 87% and 88% for children. The Allergies in America
surveys also included questions on satisfaction with treatment,
but focused on INCS. The responses were similar to those for
prescription nasal sprays in the current study.9,15 Approximately
75% of adult patients with AR and 76% of pediatric respondents
(parents and/or children) reported being somewhat or verysatisﬁed with their INCS treatment. Two parallel structured
telephone surveys of 1001 adult patients with AR in Canada
conducted in 2006 reported that 87% were satisﬁed with their
INCS treatment.18
The higher satisfaction numbers for children in the current
survey compared with the Pediatric Allergies in America data
could reﬂect changes in treatment options, access, or knowledge,
or might be due to differences in the subjects and how the data
were recorded. The current survey included only children be-
tween the ages of 12 and 17 years with seasonal nasal/ocular
allergy symptoms; the earlier study included children between
the ages of 4 and 17 years with a physician’s diagnosis of “nasal
allergy.” Sixty percent were younger than 12 years, and 62%
identiﬁed as seasonal allergy patients.9 In that study, patients
between 12 and 17 years old completed the survey along with a
parent; data presented for the current study are from only the
parent respondent.
The by-proxy assessment of patient symptom severity and/or
treatment effect can differ from direct patient assessment. For
example, in the Allergies in America survey adult patients and their
HCPs were asked how satisﬁed they (or their patients) were with
INCS treatment. More than 90% of HCPs reported that their
patients were very or somewhat satisﬁed with treatment compared
with 75% of patients.15 Likewise, parents and/or caregivers may
have a different perspective of their teenager’s morbidity and the
impact of treatment. In a recently reported pediatric clinical trial of
the intranasal combination of azelastine and ﬂuticasone propio-
nate, caregivers underestimated the effect of treatment on AR
symptoms and QoL compared with independent evaluations
completed by older children.19 This proxy confounder effect has
been reported for other allergic diseases (eg, asthma, eczema),
showing poor agreement between parent and child ratings of
morbidity and therapeutic effect.20,21 The results of this survey
TABLE V. Allergy medications used by patients at the time of the
survey
Medication class
Over the counter Prescription
Adults
(n [ 358)
Children
(n [ 324)
Adults
(n [ 298)
Children
(n [ 322)
Oral antihistamine 60% 53% 26% 41%*
Nasal antihistamine† 20% 28% 34% 33%
Nasal corticosteroid 9% 11% 24% 19%
Oral decongestant 37% 32% 13% 27%*
Nasal decongestant 26% 32% 22% 18%
Combination medicationz 18% 23% 9% 22%
NSAID 9% 11% 7% 12%
Other 6% 3% 5% 6%
None 1% 5%* 5% 6%
Not sure 11% 7% 13% 7%
NSAID, Nonsteroidal anti-inﬂammatory drug, OTC, over the counter.
Note. Respondents were asked to indicate all that applied.
*Statistically signiﬁcant compared with adult respondents at the 95% conﬁdence
level.
†Included despite no products currently on the OTC market in the United States.
zSpeciﬁc combination drug product, or drug products, was not speciﬁed. It could
have been interpreted as a single medication that contains 2 agents (eg, oral anti-
histamine/decongestant) or a single intranasal product containing 2 agents (eg,
intranasal antihistamine/corticosteroid). It also could have been interpreted as using
multiple medications or immunotherapy plus and oral medication.
0% 10% 20% 30% 40% 50% 60% 70%
Do/does not use anything
Herbal supplements
Allergy shots
PrescripƟon allergy eye drops
Vitamins
Non-prescripƟon OTC eye drops
Non-prescipƟon OTC allergy nasal spray
PrescripƟon oral allergy medicaƟon
PrescripƟon allergy nasal spray
Non-prescripƟon OTC oral allergy medicaƟon
Adults (n=500)
Children (n=501)
*
*
*StaƟsƟcally significant at 95% confidence level
FIGURE 5. How patients generally managed their/their child’s seasonal allergy (nasal/eye) symptoms. Base ¼ all qualified respondents,
N ¼ 1001. Respondents were asked to select all that applied. OTC, Over the counter.
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years should complete their own questionnaires.19,20
The reasons for potential dissatisfaction with treatment are the
same as reported in earlier studies: incomplete symptom relief
and/or perception of ineffectiveness, slow speed of onset, short
duration of relief, and side effects remain key factors.9,15,18 Some
product attributes (eg, bad taste or smell, drippiness related tothe ﬂuid volume sprayed in the nose)—real or perceived—also
may contribute to dissatisfaction and subsequently to changing,
even stopping, treatment. Thus, change and discontinuation
rates can provide an indirect measure of satisfaction.
The current survey indicates that patients using prescription
medications were not only generally more satisﬁed with treatment
effectiveness than patients taking OTC medications (approximately
80% vs 65%), but also were less likely to switch or discontinue
their treatment (approximately 20% and 35%, respectively), sup-
porting observations of greater treatment satisfaction with pre-
scription medications. In part this may reﬂect better instruction in
the clinician’s ofﬁce about how to use their medications, particu-
larly nasal sprays—a factor that was not evaluated in the survey.
Nonetheless, approximately 18% of respondents reported switch-
ing from prescription medications to solely using OTC medica-
tions, which may reﬂect changes in labeling and/or ﬁnancial/
insurance considerations. If so, the disparity between change rates
for OTC and prescription medications may diminish over time as
more prescription products become available OTC. Unfortunately,
availability will not solve the problem of 20% to 35% of patients
not perceiving the adequacy of their treatment. Approximately
70% of respondents in this survey reported that “available OTC
and within budget” is an important criterion for an allergy medi-
cation. In terms of insurance coverage, approximately 70% of
patients reported both “covered by my prescription plan” and
“available at my lowest copay” as important criteria. Interestingly,
and a cost consideration for patients, more patients reported that
their prescription medications were covered by insurance (89%)
and at the lowest copay (83%) as compared with medications
available OTC and within budget (67%). Future surveys with
similar queries will be needed to see if the treatment satisfaction
difference between prescription and OTC medications lessens or
remains the same with different access.
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Is the newest on the market
Is available OTC w/out a prescripƟon
Is available at my lowest copay
Comes in a form I/my child like(s)
Is covered by my prescripƟon plan
Is a brand I know and trust
Is available OTC w/in my budget
Works with other medicaƟons
The most eﬀecƟve allergy medicaƟon on the market
Does not cause drowsiness
Is easy to use
Gives me/my child the freedom to do more
Relieves a broad range of allergy Sx
Is fast-acƟng, provides quick relief
Has few side eﬀects
Gives consistent relief from indoor/outdoor allergy Sx
Is eﬀecƟve
Adults (n=500)
Children (n=501)
*
*
*
*StaƟsƟcally significant at 95% confidence level
FIGURE 7. Percentage of patient rating criteria for allergy medication as important. Base ¼ all respondents, N ¼ 1001. OTC, Over the
counter; Sx, symptoms.
0% 5% 10% 15% 20% 25%
PrescripƟon medicaƟons only, but changed
formulaƟon
Switched from OTC medicaƟons to only prescripƟon(s)
PrescripƟon medicaƟons only, but changed brands
Started using OTC medicaƟons to supplement
prescripƟon(s)
Started using diﬀerent types of OTC medicaƟons for
various Sx
Switched from prescripƟon medicaƟons to OTC
Switched OTC medicaƟons but same formulaƟon type
Adults (n=500)
Children (n=501)
*
*StaƟsƟcally significant at 95% confidence level
FIGURE 6. How patients’ medications for seasonal eye/nose allergy symptoms changed in recent years. Base ¼ all qualified respondents,
N ¼ 1001. Respondents were asked to select all that applied. OTC, Over the counter; Sx, symptoms.
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switch from prescription to OTC medications (19% and 13%,
respectively) and more likely to switch from OTC medications to
using only prescription medications (10% and 16%, respectively).
Children also were slightly more likely to have their prescription
brands changed, with no difference between ages for switches informulations. Although changes between formulation and brand
were not separated in the Allergies in America surveys, the data
similarly suggested that children were more likely to have their
prescription allergy medications changed than adults.9,15
The majority of respondents in this survey reported initiating
the discussion about treatment options and changing treatment
Side eﬀects (16%)
Miscellaneous  (21%)
Occurrence (35%)
Busy/forgot (36%)
No
answer 
(5%)
Costs (3%)
(Forgot/don’t remember; 
don’t like taking medicines)
(Prescribed to/Take as 
needed/ when having 
symptoms)
(Don’t want to become 
dependent/addicted) 
(Don’t have a 
prescripƟon/need refill from 
doctor; use OTC medicine) 
FIGURE 9. Reasons for not taking allergy medication as prescribed. The key within-group reasons reported by 5% of respondents are
shown in parentheses. Base ¼ 343 respondents who indicated that they or their child did not take their allergy medication exactly as
prescribed. OTC, Over the counter.
0% 20% 40% 60% 80% 100%
Is the newest on the market
Is available OTC w/out a prescripƟon
Is available at my lowest copay
Comes in a form I/my child like(s)
Is covered by my prescripƟon plan
Is a brand I know and trust
Is available OTC w/in my budget
Works with other medicaƟons
The most eﬀecƟve allergy medicaƟon on the market
Does not cause drowsiness
Is easy to use
Gives me/my child the freedom to do more
Relieves a broad range of allergy Sx
Is fast-acƟng, provides quick relief
Has few side eﬀects
Gives consistent relief from indoor/outdoor allergy Sx
Is eﬀecƟve
RaƟng criteria as important
(n=1001)
Agree that current medicaƟon
meets criteria (n=682)
FIGURE 8. Percentage of patients indicating that their current medications for seasonal allergy symptoms meet the criteria ranked as
important shown in comparison with the percentage rankings of criteria for allergy medications as important. Respondents were asked to
select all that applied. OTC, Over the counter.
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faction by empowering the patient and/or parent to take the lead
in managing their (child’s) allergic disease. Symptoms and the
negative impact of symptoms on daily life were the primary
reasons given to initiate the conversation. It has been suggested
that advertisements (TV, print, internet) or recommendations
(from family, friends) are the key drivers for patients to initiate
that discussion, but the results of this survey suggest otherwise.
Adherence with treatment for this population also appears to
be symptom driven. Most respondents reported that they (or
their child) typically take medications as prescribed or recom-
mended, but are more likely to do so when experiencingsymptoms. Related to this, the more severe the patient’s symp-
toms, the better the adherence. Given the relatively low rates of
discontinuation of treatment and switching medications, it is
relevant that the majority of patients reported that their medi-
cations met their identiﬁed “important criteria” for treatment,
namely, completeness of symptom relief, quick onset of relief,
long duration of relief, and minimal side effects. The key reasons
for lack of adherence were “forgetfulness or dislike of taking
medications” and “use only when needed.”
The outcomes of this survey suggest that the patient-treatment
paradigm may be improving. Compared with earlier surveys, it
appears that patient expectations for treatment are being met to a
0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50%
Easier to know when to refill
Taste
Is covered by my health insurance
Ease of use
Rapid onset of eﬀect
Convenient dosing schedule
Cost
Few side eﬀects (e.g., drowsiness)
Adults (n=183)
Children (n=160)
*
*
*StaƟsƟcally significant at 95% confidence level
FIGURE 10. Respondent ratings of criteria that would make it easier for respondents or their child to take allergy medications exactly as
prescribed. Base ¼ 343 respondents who indicated that they or their child did not take their allergy medication exactly as prescribed.
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10 MELTZER ETALgreater extent. Whether this reﬂects the availability of “better”
medications or whether HCPs are doing a better job of ﬁne-
tuning and explaining treatment for the individual patient is
unclear. An important outcome of earlier surveys was a recom-
mendation for patient education.4,5,9,13-18,22 In this survey, 55%
of the respondents agreed, when asked, that seasonal allergies are
a disease of the immune system, a concept that requires infor-
mation, though it is not known whether the information came
through the HCP or from some other source. Nonetheless, when
a patient understands his or her disease, adherence and satisfac-
tion with treatment improve.23 A subanalysis of treatment
satisfaction found that patients who identiﬁed seasonal allergies
as a disease of the immune system were more likely to be satisﬁed
with treatment compared with those who did not. Undeniably,
there is a continuing need to educate patients and their families
about SARC. It will be of interest to see if this trend in patient
education continues and how it relates to patient adherence and
satisfaction in future research.
Since the earlier surveys, pharmacists have taken on a larger
role in patient care, and that is reﬂected here. Approximately 4%
of the patients in this survey reported seeing a pharmacist at least
once a year for treatment. This likely reﬂects the recent move-
ment within the health care system from a primary care model to
a retail clinic model as found in some other countries.24 This
model encourages pharmacists to be part of the primary health
care team so that physicians can focus on more complex cases.25
It is a topic that needs to be further explored as the implications
for patient care are not clearly delineated.
This survey assessed the respondent’s (or child’s) symptom
experience. It was entirely conducted by patient (or parent)
perspective only, without physician oversight or guidance. Even
diagnosis was based on respondent report without a requirement
for current symptoms. Although lack of guidance may beconsidered a positive for some queries, the fact that the ques-
tionnaire was entirely based on subjective responses without use
of validated scales is an inherent limitation as is the fact that the
respondent’s interpretation of some treatments (ie, “combination
products,” “sprays”) was not deﬁned. Whether or not re-
spondents truly understood their medications is not clear.
Although 20% of adults and 28% of children were reported as
using OTC INAH, there currently are no such products available
in the US market. Also, as noted earlier, parent respondents may
have a different perspective of their teen child’s morbidity.
Other limitations are those related to the conduct of surveys.
The study sample may not represent a random sample of SARC
sufferers in the United States; respondents were recruited from a
mass mailing and then balanced and weighted to reﬂect all US
patients with SARC. Those who responded might be more likely
to do so if they had a recent bout of symptoms or were symp-
tomatic. This was not evaluated. Related to this, the survey was
conducted in early March—mid-spring hay fever season in some
regions. Patients in those regions, likely to be symptomatic or to
have more severe symptoms, might have been more likely to
respond and to seek care. However, because this retrospective
analysis had no requirement as to when patients were last
symptomatic, differences in recall time between symptoms and
survey completion might also have skewed the data. The study
was conducted online, possibly excluding potential subjects
without computer access.
The response rate for this survey was low: 1.2% (1,001 of
79,839 households contacted by email). This may also reﬂect the
online nature of the survey, though response rates for telephone
surveys have varied broadly, from 1.4% for the Pediatric Allergies
in America survey9 to as high as 25.7% for the Burden of
Rhinitis in America survey.13 Nonetheless, the ﬁndings of this
study are similar to those of earlier surveys conﬁrming the
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symptoms on QoL and productivity for the affected individual is
signiﬁcant. Despite the continued unmet needs for a still sub-
stantial percentage of the population with SARC, there appear to
be some points of encouragement with regard to satisfaction with
treatment and increased patient responsibility for management.
Continued efforts to better understand this disease and its con-
sequences, to increase access to therapy and make available newer
medications, and to deal with the challenges of management still
have the potential to further improve control of the disease and
positively modify its outcomes. Future surveys will be necessary
to conﬁrm these trends.
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RESPONDENTS
Background
Base: all respondents.
Q268 Are you.?
1 Male
2 FemaleBase: all respondents.
Q270 In what year were you born? Please enter your response as
a 4-digit number (eg, 1977).
Base: all respondents age 18D.
Q600 How many children between the ages of 12 and 17, for
who you are the parent or guardian, live in your
household?
Base: all respondents age 18D who have children.
Q605 Next, we would like to ﬁnd out the age and gender of
each child between the ages of 12 and 17 in your
household for who you are the parent or legal guardian.
For each child below, please enter his or her age and
gender.
Base: all respondents age 18D.
Q610 Have you, or any of your children aged 12-17, been told
by a doctor (diagnosed) that you have any of the following
conditions?
1 Year round nasal allergies (perennial allergic rhinitis)
2 Seasonal nasal allergies (seasonal allergic rhinitis)
3 Asthma
4 Obesity/overweight
5 Depression
6 Attention deﬁcit disorder
7 Anxiety disorders
8 Cancer
9 Diabetes
10 Sleep disorders
11 None of theseBase: child has been diagnosed with seasonal
allergies.
Q4004 You told us that your child has seasonal nasal allergies
(allergic rhinitis). For the purposes of this study, please
think about that child when answering the questions in
this survey. If you have more than one child in your
family with seasonal allergies, please think speciﬁcally
about your [AGE AND GENDER OF CHILD SUF-
FERER] when answering the questions in this survey.
Base: respondent, age 18D, and/or child aged 12-
17 suffers from seasonal allergies.
Q4005 You mentioned that [“you have” OR “your child has”]
been diagnosed with the following. Which have you
sought treatment for from a medical professional in the
past year?
1 Year round nasal allergies (perennial allergic rhinitis)
2 Seasonal nasal allergies (seasonal allergic rhinitis)3 Asthma
4 Obesity/overweight
5 Depression
6 Attention deﬁcit disorder
7 Anxiety disorders
8 Cancer
9 Diabetes
10 Sleep disorders
11 None of theseMain Survey—About Their Condition
Base: all qualified respondents.
Q105 When [(“do you”) OR (“does your child”)] experience
seasonal allergy (nasal and/or eye) symptoms? Please select
all that apply.
1 Spring
2 Summer
3 Fall
4 WinterBase: all qualified respondents.
Q110 Now, we would like to get a clearer picture of the allergies
that [(“you have”) OR (“your child has”)] and the
severity. What kinds of things trigger the seasonal allergy
symptoms [(“you have”) OR (“your child has”)]? Please
select all that apply.
1 Tree pollen
2 Grass pollen
3 Weed pollen
4 Mold spores
5 Other—specify
6 Do not knowBase: all qualified respondents.
Q115 When are [(“your”) OR (“your child’s”)] seasonal allergy
symptoms the worst? Please select one.
1 Spring
2 Summer
3 Fall
4 WinterBase: all qualified respondents.
Q120 Generally, how would you classify [(“your”) OR (“your
child’s”)] allergy symptoms for each season? 1, Mild; 2,
Moderate; 3, Severe
1 Spring
2 Summer
3 Fall
4 WinterBase: all qualified respondents.
Q130 When experiencing seasonal allergy symptoms, how
frequently [(“do you”) OR (“does your child”)] suffer
from them?
1 Less than once a month
2 Monthly
3 Weekly
4 Daily
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Q135 At what age [(“were you”) OR (“was your child”)] ﬁrst
diagnosed with seasonal allergies?
Base: all qualified respondents.
Q140 What is the most bothersome allergy symptom that
[(“you seek”) OR (“your child seeks”)] treatment for?
Please select one.
1 Runny nose
2 Stuffy nose
3 Itching
4 Itchy eyes
5 Congestion
6 Sneezing
7 Headaches/sinus pain
8 None of theseBase: all qualified respondents.
Q145 Which of the following words, if any, describe how [(“you
feel”) OR (“your child feels”)] when suffering from sea-
sonal allergy (nasal and/or eye) symptoms? Please select
all that apply.
1 Angry
2 Unhappy
3 Distracted
4 Having poor concentration
5 Embarrassed
6 Frustrated
7 Irritable
8 Tired
9 Upset
10 Unattractive
11 Unproductive/having reduced productivity
12 Unable to perform at [(“my”) OR (“his or her”)] best
13 Less conﬁdent
14 Indifferent/don’t care
15 None of theseBase: all qualified respondents.
Q150 At what age did [(“you”) OR (“your child”)] ﬁrst start
taking medications to treat [(“your”) OR (“his or her”)]
seasonal allergy (nasal and/or eye) symptoms?
Base: all qualified respondents.
Q155 The next few questions are about [(“your”) OR (“your
child’s”)] allergies when [(“you don’t”) OR (“he or she
doesn’t”)] take [(“your”) OR (“his or her”)] allergy
medication. Please think back to those times when [(“you
have not taken your”) OR (“your child has not taken his
or her”)] seasonal allergy medications. How would you
describe [(“your”) OR (“his or her”)] symptoms?
1 Mild
2 Moderate
3 SevereBase: all qualified respondents.
Q160 Using the scale below, how severe would you say each of
the following allergy symptoms is when [(“you have”) OR(“your child has”)] not taken medication to treat it? 1,
Not at all severe; 2, Mildly severe; 3, Very severe
1 Nasal congestion
2 Runny nose
3 Stuffy Nose
4 Sneezing
5 Itching
6 Itchy eyes
7 Headaches/sinus painBase: all qualified respondents.
Q165 Using the scale below, how much do [(“your”) OR (“your
child’s”)] seasonal allergy symptoms (nasal and/or eye)
interfere with each of the following? 1, Not at all; 2, A
little; 3, A lot
1 Productivity at work or school
2 Leisure/social activities
3 SleepBase: allergies interfered with work or school.
Q170 Allergies can often make people feel that they are less
productive at work or school. During a month when
[(“you typically suffer”) OR (“your child typically suf-
fers”)] from seasonal allergies (nasal and/or eye), how
many days of work or school would you say [(“you were”)
OR (“your child was”)] less productive than [(“you usu-
ally are”) OR (“your child usually is”)] on account of
[(“your”) OR (“their”)] seasonal allergies?
1 None
2 1-5 days
3 6-10 days
4 11-20 days
5 21-30 days
6 Don’t knowMain Survey—Treatment Options, Awareness, and
Usage
Base: all qualified respondents.
Q200 [(“Have you”) OR (“Has your child”)] seen a doctor and
been tested for seasonal allergies?
1 Yes
2 NoBase: all qualified respondents.
Q205 What took place before [(“you”) OR (“your child”)]
visiting the doctor to get tested for seasonal allergies (nasal
and/or eye)? Please select all that apply.
1 [(“I”) OR (“My child”)] suffered from some seasonal
allergy symptoms such as itchy eyes, runny nose, and
sneezing.
2 [(“I”) OR (“My child”)] tried some over-the-counter
products based on advertising I saw about seasonal al-
lergy symptoms.
3 [(“I”) OR (“My child”)] tried some over-the-counter
products based on a friend’s recommendation.
4 [(“I”) OR (“My child”)] tried some over-the-counter
products based on a pharmacist’s recommendation.
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products based on reading the labels of multiple
products in the store.
6 [(“I”) OR (“My child”)] had to take time off of work/
school because symptoms were so bad.
7 None of these.Base: all qualified respondents.
Q210 Which, if any, of the following doctors or health care
professionals have you seen about [(“your”) OR (“your
child’s”)] seasonal allergy symptoms (nasal and/or eye)?
Please select all that apply.
1 Primary care physician
2 Allergy specialist
3 Ear, nose, and throat specialist
4 Pediatrician
5 Pharmacist
6 Nurse practitioner
7 Other health care professional
8 NoneBase: all qualified respondents.
Q215 Which of the following doctors/health care professionals,
if any, are currently treating [(“your”) OR (“your
child’s”)] seasonal allergy symptoms (nasal and/or eye)?
Please select all that apply.
1 Primary care physician
2 Allergy specialist
3 Ear, nose, and throat specialist
4 Pediatrician
5 Pharmacist
6 Nurse practitioner
7 Other health care professional—specify
8 NoneBase: all qualified respondents.
Q220 True or false; seasonal allergies are a disease of the im-
mune system. Please select one.
1 True
2 FalseBase: all qualified respondents who have seen a
health care professional.
Q225 How often do [(“you go”) OR (“you take your child”)] to
each of the following health care professionals listed below
due to [(“your”) OR (“your child’s”)] seasonal allergy
symptoms (nasal and/or eye)?
1 Once a year or less often
2 2-3 times a year
3 4-6 times a year
4 7-11 times a year
5 More than once a month
1 Primary care physician
2 Allergy specialist
3 Ear, nose, and throat specialist
4 Pediatrician
5 Pharmacist
6 Nurse practitioner
7 [OTHER FROM SPECIFY AT Q215]Base: all qualified respondents.
Q230 When talking to your doctor about prescription treat-
ments for [(“your”) OR (“your child’s”)] seasonal allergies
(nasal and/or eye), who initiates the discussion about
different treatment options/choices? Please select only one
answer.
1 I initiate the discussion.
2 I initiate the discussion after seeing a TV ad for a
speciﬁc prescription allergy medication.
3 I initiate the discussion after seeing a print ad for a
speciﬁc prescription allergy medication.
4 I initiate the discussion after seeing an internet ad for a
speciﬁc prescription allergy medication.
5 I initiate the discussion after a recommendation from a
friend or family member.
6 My doctor initiates the discussion.Base: all qualified respondents.
Q235 How [(“do you”) OR (“does your child”)] generally
manage [(“your”) OR (“his or her”)] seasonal allergy
symptoms (nasal and/or eye)? Please select all that apply.
1 Allergy shots
2 Prescription oral allergy medication
3 Prescription allergy nasal spray
4 Prescription allergy eye drops
5 Nonprescription/over-the-counter oral allergy
medication
6 Nonprescription/over-the-counter allergy nasal spray
7 Nonprescription/over-the-counter allergy eye drops
8 Vitamins
9 Herbal supplements
10 [(“I don’t take”) OR (“My child does not take”)]/use
anythingBase: all qualified respondents who use at least one
medication to treat seasonal allergy symptoms.
Q240 How satisﬁed are you with the effectiveness of each of the
following types of medication [(“you use”) OR (“your
child uses”)] to relieve [(“your”) OR (“his or her”)] sea-
sonal allergy symptoms? Scale: 1, Not at all satisﬁed; 2,
Somewhat satisﬁed; 3, Satisﬁed; 4, Very satisﬁed; 5,
Extremely satisﬁed
1 Allergy shots
2 Prescription oral allergy medication
3 Prescription seasonal nasal spray
4 Prescription allergy eye drops
5 Nonprescription/over-the-counter oral allergy
medication
6 Nonprescription/over-the-counter seasonal spray
7 Nonprescription/over-the-counter allergy eye dropsBase: all qualified respondents.
Q245 Which of the following type(s) of allergy medication
[(“are you”) OR (“is your child”)] using? Please select all
that apply. Indicate: 1, Over-the-counter; 2, Prescription
1 Oral antihistamine
2 Nasal antihistamine
3 Nasal corticosteroid
4 Oral decongestant
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6 Nonsteroidal anti-inﬂammatory
7 Combination medicines
8 Other
9 None
10 Not sureBase: all qualified respondents.
Q250 How has the treatment of [(“your”) OR (“your child’s”)]
seasonal allergy symptoms (nasal and/or eye) changed in
recent years? Please select one.
1 [(“I have”) OR (“My child has”)] only ever taken
medications prescribed by [(“my”) OR (“his or her”)]
doctor, but the brand of medication has changed over
time.
2 [(“I have”) OR (“My child has”)] only ever taken
medications prescribed by [(“my”) OR (“his or her”)]
doctor, but the form of medication has changed over
time (eg, from oral medication to nasal sprays or vice
versa).
3 [(“I have”) OR (“My child has”)] begun taking over-
the-counter medications to supplement the pre-
scriptions [(“my”) OR (“his or her”)] doctor has
prescribed.
4 [(“I have”) OR (“My child has”)] [(“I have”) OR (“My
child has”)] switched from taking prescription medi-
cations to using only over-the-counter medications.
5 [(“I have”) OR (“My child has”)] [(“I have”) OR (“My
child has”)] switched brands of over-the-counter
medication but [(“am”) OR (“is”)] using the same
type of medication (eg, nasal spray, oral medication,
etc.).
6 [(“I have”) OR (“My child has”)] switched from taking
only over-the-counter medications to using only those
prescribed by a doctor.
7 [(“I have”) OR (“My child has”)] started taking
different kinds of over-the-counter medication to treat
[(“my”) OR (“their”)] various symptoms.Base: all qualified respondents.
Q255 When do you typically re-evaluate the care [(“you
receive”) OR (“your child receives”)] for seasonal allergies
(nasal and/or eye)? Please select all that apply.
1 At the beginning of every allergy season
2 Only when changes are made to [(“my”) OR (“my
child’s”)] health insurance
3 When [(“I change”) OR (“my child changes”)] primary
care physicians
4 When symptoms are no longer managed with current
care
5 None of the aboveBase: all qualified respondents.
Q260 When [(“do you”) OR (“does your child”)] typically start
taking [(“your”) OR (“his or her”)] medication to treat
[(“your”) OR (“their”)] seasonal allergy symptoms (nasal
and/or eye)? Please select one.
1 Before allergy season starts
2 At the start of [(“my”) OR (“their”)] allergy season
before any symptoms start3 Only when [(“I have”) OR (“my child has”)] symptoms
4 When symptoms ﬁrst arise and continue taking until
they subside
5 Every day to ward off symptoms
6 Constantly, [(“I always seem”) OR (“my child always
seems”)] to be on some type of seasonal allergy
medication.Base: all qualified respondents.
Q265 Which of the following is closer to [(“your”) OR (“your
child’s”)] situation? Please select one.
1 [(“I only take”) OR (“My child only takes”)] medica-
tions to treat [(“my”) OR (“their”)] seasonal allergies
that [(“my”) OR (“their”)] doctor prescribes or over-
the-counter medication that [(“my”) OR (“their”)]
doctor or pharmacist recommends.
2 [(“I take”) OR (“My child takes”)] some medications
[(“my”) OR (“their”)] doctor prescribes or recommends
but sometimes add over-the-counter medications to
treat speciﬁc symptoms.
3 [(“I take”) OR (“My child takes”)] over-the-counter
medications that I choose without the beneﬁt of
[(“my”) OR (“their”)] doctors’ recommendation.
4 None of theseBase: uses prescription medications.
Q270 Would you say the prescription medications [(“you take”)
OR (“your child takes”)] for [(“your”) OR (“his or her”)]
seasonal allergies (nasal and/or eye) have become more or
less expensive over the last year?
1 More expensive
2 Less expensive
3 About the sameBase: uses over-the-counter medications.
Q275 Would you say the over-the-counter medications [(“you
take”) OR (“your child takes”)] for [(“your”) OR (“his or
her”)] seasonal allergies (nasal and/or eye) have become
more or less expensive over the last year?
1 More expensive
2 Less expensive
3 About the sameBase: all qualified respondents.
Q280 How important is it to you that [(“your”) OR (“your
child’s”)] seasonal allergy medication (nasal and/or eye)
meets each of the following criteria? Scale: 1, Not at all
important; 2, Somewhat important; 3, Very important; 4,
Extremely important
1 Is the newest on the market
2 Is the most effective allergy medication on the market
3 Is effective
4 Gives [(“me”) OR (“my child”)] the freedom to do
more of what [(“I”) OR (“they”)] want to do
5 Is fast acting/provides quick relief
6 Does not cause drowsiness
7 Relieves a broad range of allergy symptoms
8 Is easy to use
9 Has few side effects
TABLE E1. Frequency with which patients saw their health care
professional for their seasonal nasal and/or ocular allergy
symptoms
Health care professional Adults Children
Primary care
Primary care physician n ¼ 280 n ¼ 185
1/y 34% 23%
2-3/y 47% 44%
4-6/y 12% 27%*
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11.e5 MELTZER ETAL10 Is a brand I know and trust
11 Provides consistent relief from [(“my”) OR (“my
child’s”)] indoor and outdoor allergy symptoms
12 Is covered by my prescription plan
13 Is available at my lowest copay
14 Is available over the counter and without a doctor’s
prescription
15 Is available over the counter and is within my budget
16 Works with other medications to provide treatment
17 Comes in a form [(“I like”) OR (“my child likes”)]7-11/y 6% 5%
1/mo 0 1%
Pediatrician n ¼ 2 n ¼ 156
 1/y 77% 23%
2-3/y 23% 54%
4-6/y e 17%
7-11/y e 3%
1/mo e 2%Base: Currently using seasonal allergy medications.
Q285 Thinking about the medications [(“you take”) OR (“your
child takes”)], how strongly do you agree or disagree that
your current prescription seasonal allergy medication
meets each of the following criteria? Scale: 1, Strongly
disagree; 2, Somewhat disagree; 3, Somewhat agree; 4,
Strongly agreeNurse practitioner n ¼ 33 n ¼ 31
1/y 33% 24%
2-3/y 37% 40%
4-6/y 11% 17%
7-11/y 19% 16%
1/mo 1% 4%
Allergy or ear, nose, throat specialist
Allergy specialist n ¼ 70 n ¼ 110
1/y 32% 21%
2-3/y 30% 36%
4-6/y 20% 23%
7-11/y 6% 10%
1/mo 12% 10%
Ear, nose, throat specialist n ¼ 44 n ¼ 41
1/y 45% 26%
2-3/y 45% 42%
4-6/y 5% 21%
7-11/y 2% 3%1 Is the newest on the market
2 Is the most effective allergy medication on the market
3 Is effective
4 Gives [(“me”) OR (“my child”)] the freedom to do
more of what [(“I”) OR (“they”)] want to do
5 Is fast acting/provides quick relief
6 Does not cause drowsiness
7 Relieves a broad range of allergy symptoms
8 Is easy to use
9 Has few side effects
10 Is a brand I know and trust
11 Provides consistent relief from [(“my”) OR (“my
child’s”)] indoor and outdoor allergy symptoms
12 Is covered by my prescription plan
13 Is available at my lowest copay
14 Is available over the counter without a doctor’s
prescription
15 Is available over the counter and is within my budget
16 Comes in a form [(“I like”) OR (“my child likes”)]1/mo 3% 7%
Other
Pharmacist n ¼ 20 n ¼ 18
1/y 17% 19%
2-3/y 50% 61%
4-6/y 16% 18%
7-11/y 9% 2%
1/mo 7% eMain Survey—Compliance
Base: all qualified respondents.
Q300 Is the way [(“you take”) OR (“your child takes”)]
[(“your”) OR (“his or her”)] allergy medications exactly as
the doctor prescribed (eg, taken daily or 2 times per day as
the doctor indicated)?Speciﬁed by respondent† n ¼ 16 n ¼ 3
1/y 47% e
2-3/y 37% 51%
4-6/y 16% 49%
7-11/y e e
1/mo e e
*Statistically signiﬁcant compared with adult respondents at the 95% conﬁdence
level.
†Included asthma specialist, dermatologist, homeopath, internist, neurologist,1 Yes, [(“I always take”) OR (“my child always takes”)]
[(“my”) OR (“his or her”)] allergy medications exactly
as the doctor prescribed.
2 No, [(“I try”) OR (“my child tries”)] to take [(“my”)
OR (“his or her”)] antiallergy medications as pre-
scribed, but sometimes [(“I am”) OR (“he or she is”)]
not able to.
3 No, [(“I take”) OR (“he or she takes”)] [(“my”) OR
(“his or her”)] antiallergy medications only when [(“I
have”) OR (“my child has”)] symptoms.ophthalmologist, physician assistant, and pulmonologist as speciﬁed by respondents.Base: does not take medications as prescribed.
Q305
Why [(“don’t you take”) OR (“doesn’t your child take”)]
[(“your”) OR (“his or her”)] allergy medication as prescribed?
[OPEN END TEXT BOX]Base: does not take medications as prescribed.
Q306 What would make it easier for [(“you”) OR (“your
child”)] to take [(“your”) OR (“his or her”)] allergy
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apply.
1 Cost
2 Easier to know when to reﬁll
3 Taste
4 Ease of use5 Convenient dosing schedule
6 Few side effects (eg, drowsiness)
7 Rapid onset of effect
8 Is covered by my health insurance
